Literature DB >> 29107709

IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.

Thomas R O'Brien1, Shyam Kottilil2, Ruth M Pfeiffer3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29107709      PMCID： PMC7390973          DOI： 10.1053/j.gastro.2017.06.069

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  7 in total

1.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Authors:  Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien
Journal:  Nat Genet       Date:  2013-01-06       Impact factor: 38.330

2.  The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.

Authors:  Feng Su; Pamela K Green; Kristin Berry; George N Ioannou
Journal:  Hepatology       Date:  2016-12-24       Impact factor: 17.425

3.  Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Authors:  Susanna Naggie; Curtis Cooper; Michael Saag; Kimberly Workowski; Peter Ruane; William J Towner; Kristen Marks; Anne Luetkemeyer; Rachel P Baden; Paul E Sax; Edward Gane; Jorge Santana-Bagur; Luisa M Stamm; Jenny C Yang; Polina German; Hadas Dvory-Sobol; Liyun Ni; Phillip S Pang; John G McHutchison; Catherine A M Stedman; Javier O Morales-Ramirez; Norbert Bräu; Dushyantha Jayaweera; Amy E Colson; Pablo Tebas; David K Wong; Douglas Dieterich; Mark Sulkowski
Journal:  N Engl J Med       Date:  2015-07-21       Impact factor: 91.245

4.  Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.

Authors:  Ira M Jacobson; Eric Lawitz; Edward J Gane; Bernard E Willems; Peter J Ruane; Ronald G Nahass; Sergio M Borgia; Stephen D Shafran; Kimberly A Workowski; Brian Pearlman; Robert H Hyland; Luisa M Stamm; Evguenia Svarovskaia; Hadas Dvory-Sobol; Yanni Zhu; G Mani Subramanian; Diana M Brainard; John G McHutchison; Norbert Bräu; Thomas Berg; Kosh Agarwal; Bal Raj Bhandari; Mitchell Davis; Jordan J Feld; Gregory J Dore; Catherine A M Stedman; Alexander J Thompson; Tarik Asselah; Stuart K Roberts; Graham R Foster
Journal:  Gastroenterology       Date:  2017-04-05       Impact factor: 22.682

5.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

6.  Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.

Authors:  Thomas R O'Brien; Krystle A Lang Kuhs; Ruth M Pfeiffer
Journal:  Open Forum Infect Dis       Date:  2014-12-13       Impact factor: 3.835

7.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962
  7 in total
  7 in total

1.  Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential.

Authors:  Thomas R O'Brien; Howard A Young; Raymond P Donnelly; Ludmila Prokunina-Olsson
Journal:  J Interferon Cytokine Res       Date:  2019-04-17       Impact factor: 2.607

2.  Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population.

Authors:  Bisma Rauff; Ali Amar; Shafiq Ahmad Chudhary; Saqib Mahmood; Ghias Un Nabi Tayyab; Rumeza Hanif
Journal:  Arch Virol       Date:  2021-02-02       Impact factor: 2.574

Review 3.  What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?

Authors:  Thomas R O'Brien; Sarah S Jackson
Journal:  J Interferon Cytokine Res       Date:  2019-06-04       Impact factor: 2.607

4.  IFNL4 haplotype, linkage disequilibrium and their influence on virological response to hepatitis C virus infection in Indian population.

Authors:  Neelanjana Roy; Chandreswar Prasad; Anand Kumar; Krishnendu Mondol; Kajal Jain; Renu Yadav; Jyotish Kumar Jha; Neeti Nadda; Subrat Kumar Acharya; Baibaswata Nayak
Journal:  Virusdisease       Date:  2019-07-24

Review 5.  Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals.

Authors:  Pil Soo Sung; Eui-Cheol Shin
Journal:  Int J Mol Sci       Date:  2020-04-08       Impact factor: 5.923

6.  Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients.

Authors:  Seham Mahrous Zaki; Hanan Samir Ahmed; Monkez Motieh Yousif; Eman Mohamed Awad
Journal:  Trop Med Infect Dis       Date:  2022-09-05

7.  Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis.

Authors:  Christopher R Jones; Barnaby F Flower; Ella Barber; Bryony Simmons; Graham S Cooke
Journal:  Wellcome Open Res       Date:  2019-09-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.